XXXX : the Dutch experience and review of the literature.

@entity1 @entity981 @entity3052 @entity828 @entity1778 @entity2008
We reviewed Dutch @entity1 and those described in the literature with @entity1778 in the past 25 years, with the intention to obtain an overview of the characteristics of this rare disease. Among the 117 @entity1 reviewed, @entity3052 ( @entity3052 ) was more frequent (64%) than @entity981 ( @entity981 , 21%). Most @entity1 had a high leukaemic cell load with @entity828 , @entity1778 and hyperleucocytosis. @entity2008 were found in the majority of the @entity1 tested (72%); 11q23 abnormalities were found in less than half of them (42%). The probability of overall survival at 24 months was only 23%. When @entity3052 and @entity981 were compared, clinical characteristics and overall survival were not significantly different. However, in @entity1 at risk, the probability of event-free survival (EFS) and disease-free survival (DFS) were significantly higher in @entity3052 than in @entity981 , 43% versus 13% and 68% versus 0% respectively. Among the @entity3052 cases, six spontaneous remissions have been described. In conclusion, the clinical characteristics of @entity1778 differ from those of @entity1778 in older @entity1 and prognosis is generally poor. Once complete remission is achieved, @entity1 with @entity3052 fare better than those with @entity981 . Chemotherapy for @entity1778 needs improvement to increase the sustained remission rate.
